{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T16:31:13Z","timestamp":1783960273738,"version":"3.55.0"},"reference-count":187,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Shire Development LLC"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.pharmthera.2014.03.005","type":"journal-article","created":{"date-parts":[[2014,3,21]],"date-time":"2014-03-21T20:31:07Z","timestamp":1395433867000},"page":"253-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Preclinical pharmacology of amphetamine: Implications for the treatment of neuropsychiatric disorders"],"prefix":"10.1016","volume":"143","author":[{"given":"Peter H.","family":"Hutson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank I.","family":"Tarazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Madhoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Slawecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin A.","family":"Patkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2014.03.005_bb0005","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0022-3565(24)36622-4","article-title":"Nonstriatal dopamine D1 receptors regulate striatal acetylcholine release in vivo","volume":"281","author":"Acquas","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0010","doi-asserted-by":"crossref","first-page":"694","DOI":"10.4088\/JCP.12m08144","article-title":"Lisdexamfetamine dimesylate in adults with attention-deficit\/hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study","volume":"74","author":"Adler","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0015","doi-asserted-by":"crossref","first-page":"6689","DOI":"10.1523\/JNEUROSCI.4453-09.2010","article-title":"IP3 receptor sensitization during in vivo amphetamine experience enhances NMDA receptor plasticity in dopamine neurons of the ventral tegmental area","volume":"30","author":"Ahn","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0020","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.euroneuro.2007.03.002","article-title":"Chronic amphetamine treatment reduces NGF and BDNF in the rat brain","volume":"17","author":"Angelucci","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0025","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF00428187","article-title":"Amphetamine response and relapse risk after depot neuroleptic discontinuation","volume":"85","author":"Angrist","year":"1985","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0030","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0006-8993(00)03328-X","article-title":"Amphetamine-stimulated cortical acetylcholine release: role of the basal forebrain","volume":"894","author":"Arnold","year":"2001","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0035","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.biopsych.2004.08.019","article-title":"Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions","volume":"57","author":"Arnsten","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0040","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1124\/pr.111.005108","article-title":"Brain-derived neurotrophic factor and neuropsychiatric disorders","volume":"64","author":"Autry","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0045","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/10673229609017200","article-title":"Brain dopamine receptors: a primer on their current status, basic and clinical","volume":"3","author":"Baldessarini","year":"1996","journal-title":"Harv Rev Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/DDDT.S11859","article-title":"The use of serotonergic drugs to treat obesity\u2014is there any hope?","volume":"5","author":"Bello","year":"2011","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0055","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1038\/npp.2012.108","article-title":"Altered acquisition and extinction of amphetamine-paired context conditioning in genetic mouse models of altered NMDA receptor function","volume":"37","author":"Benneyworth","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0060","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/mp.2008.90","article-title":"Potential adverse effects of amphetamine treatment on brain and behavior: a review","volume":"14","author":"Berman","year":"2009","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/JOE-10-0069","article-title":"New concepts in prolactin biology","volume":"206","author":"Bernichtein","year":"2010","journal-title":"J Endocrinol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0075","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-006-0578-x","article-title":"The debate over dopamine's role in reward: the case for incentive salience","volume":"191","author":"Berridge","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0070","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0165-0173(03)00143-7","article-title":"The locus coeruleus\u2013noradrenergic system: modulation of behavioral state and state-dependent cognitive processes","volume":"42","author":"Berridge","year":"2003","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0080","first-page":"113","article-title":"Effects of the cannabinoid receptor ligands on anxiety-related effects of d-amphetamine and nicotine in the mouse elevated plus maze test","volume":"60","author":"Biala","year":"2009","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0085","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.pbb.2011.05.002","article-title":"Cognitive enhancers for the treatment of ADHD","volume":"99","author":"Bidwell","year":"2011","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0090","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1017\/S003329170500499X","article-title":"Executive functioning in adult ADHD: a meta-analytic review","volume":"35","author":"Boonstra","year":"2005","journal-title":"Psychol Med"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0095","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.neuropharm.2008.06.017","article-title":"The selective delta opioid agonist SNC80 enhances amphetamine-mediated efflux of dopamine from rat striatum","volume":"55","author":"Bosse","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0100","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11920-008-0065-7","article-title":"ADD\/ADHD and impaired executive function in clinical practice","volume":"10","author":"Brown","year":"2008","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0105","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1471-4159.2010.06921.x","article-title":"Amphetamine regulates NR2B expression in Go2alpha knockout mice and thereby sustains behavioral sensitization","volume":"115","author":"Brunk","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0110","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.pnpbp.2010.10.019","article-title":"Psychomotor retardation in depression: biological underpinnings, measurement, and treatment","volume":"35","author":"Buyukdura","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0115","first-page":"CD006722","article-title":"Psychostimulants for depression","author":"Candy","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0120","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1399-5618.2004.00132.x","article-title":"Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation","volume":"6","author":"Carlson","year":"2004","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0125","doi-asserted-by":"crossref","first-page":"471","DOI":"10.31887\/DCNS.2010.12.4\/ycharnay","article-title":"Brain serotonergic circuitries","volume":"12","author":"Charnay","year":"2010","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0130","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1124\/jpet.108.147959","article-title":"Protein kinase C\u03b2 is a critical regulator of dopamine transporter trafficking and regulates the behavioral response to amphetamine in mice","volume":"328","author":"Chen","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0135","first-page":"565","article-title":"Amphetamine increases phosphorylation of extracellular signal-regulated kinase and transcription factors in the rat striatum via group I metabotropic glutamate receptors","volume":"27","author":"Choe","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0140","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.biopsych.2012.01.027","article-title":"Endogenous opioid release in the human brain reward system induced by acute amphetamine administration","volume":"72","author":"Colasanti","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0145","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.tics.2007.10.011","article-title":"Serotoninergic regulation of emotional and behavioural control processes","volume":"12","author":"Cools","year":"2008","journal-title":"Trends Cogn Sci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0150","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1152\/physrev.00022.2010","article-title":"What genetics tells us about the causes and mechanisms of Parkinson's disease","volume":"91","author":"Corti","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0155","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/00004647-200205000-00011","article-title":"Specific binding of [(11)C]raclopride and N-[(3)H]propyl-norapomorphine to dopamine receptors in living mouse striatum: occupancy by endogenous dopamine and guanosine triphosphate-free G protein","volume":"22","author":"Cumming","year":"2002","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0160","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1523\/JNEUROSCI.2136-12.2013","article-title":"Amphetamine paradoxically augments exocytotic dopamine release and phasic dopamine signals","volume":"33","author":"Daberkow","year":"2013","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0165","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1146\/annurev.pharmtox.47.120505.105214","article-title":"Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system","volume":"47","author":"Dani","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0170","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.neubiorev.2007.02.004","article-title":"Neurobiological mechanisms for the regulation of mammalian sleep\u2013wake behavior: reinterpretation of historical evidence and inclusion of contemporary cellular and molecular evidence","volume":"31","author":"Datta","year":"2007","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0175","doi-asserted-by":"crossref","first-page":"e04","DOI":"10.4088\/JCP.9058se1c.04gry","article-title":"Major depressive disorder treatment guidelines in America and Europe","volume":"71","author":"Davidson","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0180","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/syn.890120405","article-title":"Dopaminergic regulation of cortical acetylcholine release","volume":"12","author":"Day","year":"1992","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0185","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1046\/j.1471-4159.1994.63062086.x","article-title":"Dopaminergic regulation of septohippocampal cholinergic neurons","volume":"63","author":"Day","year":"1994","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0190","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.4088\/JCP.v64n0911","article-title":"Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study","volume":"64","author":"DeBattista","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0195","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1124\/mol.106.026690","article-title":"Amphetamine induces a calcium\/calmodulin-dependent protein kinase II-dependent reduction in norepinephrine transporter surface expression linked to changes in syntaxin 1A\/transporter complexes","volume":"71","author":"Dipace","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0200","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.pbb.2010.05.005","article-title":"Age-related differences in amphetamine sensitization: effects of prior drug or stress history on stimulant sensitization in juvenile and adult rats","volume":"96","author":"Doremus-Fitzwater","year":"2010","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0205","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pbb.2011.02.022","article-title":"The cholinergic hypothesis of cognitive aging revisited again: cholinergic functional compensation","volume":"99","author":"Dumas","year":"2011","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0210","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/jcp.0b013e31815abefb","article-title":"Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study","volume":"27","author":"Dunlop","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0215","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1517\/17425255.2012.671295","article-title":"Metabolic, toxicological, and safety considerations for drugs used to treat ADHD","volume":"8","author":"Duong","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0220","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1126\/science.1222941","article-title":"Depression and hippocampal neurogenesis: a road to remission?","volume":"338","author":"Eisch","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0230","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1755-5949.2010.00146.x","article-title":"Relevance of norepinephrine\u2013dopamine interactions in the treatment of major depressive disorder","volume":"16","author":"El Mansari","year":"2010","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0225","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00213-009-1690-5","article-title":"Restoration of amphetamine-induced locomotor sensitization in dopamine D1 receptor-deficient mice","volume":"207","author":"El-Ghundi","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0235","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1098\/rstb.2000.0787","article-title":"The neurobiology and evolution of cannabinoid signalling","volume":"356","author":"Elphick","year":"2001","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0240","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2174\/187152708786927886","article-title":"The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy","volume":"7","author":"Engleman","year":"2008","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0245","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bbr.2012.03.027","article-title":"Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse","volume":"231","author":"Enman","year":"2012","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0250","first-page":"678","article-title":"Using meta-analysis to compare the efficacy of medications for attention-deficit\/hyperactivity disorder in youths","volume":"34","author":"Faraone","year":"2009","journal-title":"Phys Ther"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0255","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4088\/JCP.v66n0112","article-title":"A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness","volume":"66","author":"Fava","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0260","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0304-3940(96)12963-3","article-title":"Amphetamine releases dopamine from synaptic vesicles by dual mechanisms","volume":"215","author":"Floor","year":"1996","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0265","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0306-4522(00)00115-9","article-title":"Changes in astrocytic basic fibroblast growth factor expression during and after prolonged exposure to escalating doses of amphetamine","volume":"98","author":"Flores","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0270","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1152\/physrev.00004.2003","article-title":"Role of endogenous cannabinoids in synaptic signaling","volume":"83","author":"Freund","year":"2003","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0275","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.drugalcdep.2011.12.026","article-title":"Differential effects of intermittent and continuous exposure to novel environmental stimuli on the development of amphetamine-induced behavioral sensitization in mice: implications for addiction","volume":"124","author":"Fukushiro","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0280","first-page":"412","article-title":"Dextroamphetamine treatment of mania","volume":"48","author":"Garvey","year":"1987","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0285","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/cercor\/10.10.952","article-title":"Structural synaptic modifications associated with hippocampal LTP and behavioral learning","volume":"10","author":"Geinisman","year":"2000","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0290","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/(SICI)1096-9861(20000131)417:1<49::AID-CNE4>3.0.CO;2-3","article-title":"Remodeling of hippocampal synapses after hippocampus-dependent associative learning","volume":"417","author":"Geinisman","year":"2000","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0295","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1399-5618.2012.00995.x","article-title":"Cognition in older adults with bipolar disorder versus major depressive disorder","volume":"14","author":"Gildengers","year":"2012","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0300","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1523\/JNEUROSCI.21-16-06362.2001","article-title":"Amphetamine-induced plasticity of AMPA receptors in the ventral tegmental area: effects on extracellular levels of dopamine and glutamate in freely moving rats","volume":"21","author":"Giorgetti","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0305","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/schbul\/23.3.437","article-title":"Functional and anatomical aspects of prefrontal pathology in schizophrenia","volume":"23","author":"Goldman-Rakic","year":"1997","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0310","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/schbul\/sbs010","article-title":"NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia","volume":"38","author":"Gonzalez-Burgos","year":"2012","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0315","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1369-1600.2011.00362.x","article-title":"Periadolescent amphetamine treatment causes transient cognitive disruptions and long-term changes in hippocampal LTP depending on the endogenous expression of pleiotrophin","volume":"18","author":"Gramage","year":"2013","journal-title":"Addict Biol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0320","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1523\/JNEUROSCI.23-03-00742.2003","article-title":"Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving","volume":"23","author":"Grimm","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0325","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1369-1600.2009.00150.x","article-title":"The effect of naltrexone on amphetamine-induced conditioned place preference and locomotor behaviour in the rat","volume":"14","author":"Haggkvist","year":"2009","journal-title":"Addict Biol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0330","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bbr.2008.08.021","article-title":"The opioid receptor antagonist naltrexone attenuates reinstatement of amphetamine drug-seeking in the rat","volume":"197","author":"Haggkvist","year":"2009","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0335","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.conb.2006.09.002","article-title":"The role of acetylcholine in learning and memory","volume":"16","author":"Hasselmo","year":"2006","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0340","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.neubiorev.2011.03.005","article-title":"5-HT receptors and reward-related behaviour: a review","volume":"35","author":"Hayes","year":"2011","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0345","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.neuropharm.2009.08.020","article-title":"The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety","volume":"57","author":"Heal","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0350","doi-asserted-by":"crossref","first-page":"11","DOI":"10.31887\/DCNS.2013.15.1\/jhenley","article-title":"AMPA receptor trafficking and the mechanisms underlying synaptic plasticity and cognitive aging","volume":"15","author":"Henley","year":"2013","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0355","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neuroscience.2012.01.015","article-title":"Effect of amphetamine place conditioning on excitatory synaptic events in the basolateral amygdala ex vivo","volume":"206","author":"Hetzel","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0360","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11940-011-0137-6","article-title":"Recent advances in the treatment of narcolepsy","volume":"13","author":"Hirai","year":"2011","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0365","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/11599630-000000000-00000","article-title":"The pharmacology and clinical outcomes of amphetamines to treat ADHD: does composition matter?","volume":"26","author":"Hodgkins","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0370","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1523\/JNEUROSCI.19-10-04110.1999","article-title":"Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor","volume":"19","author":"Horger","year":"1999","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0375","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III\u2014the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0380","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1476-5381.2011.01364.x","article-title":"Endocannabinoid tone versus constitutive activity of cannabinoid receptors","volume":"163","author":"Howlett","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0385","doi-asserted-by":"crossref","first-page":"10311","DOI":"10.1523\/JNEUROSCI.23-32-10311.2003","article-title":"Mediation of amphetamine-induced long-term depression of synaptic transmission by CB1 cannabinoid receptors in the rat amygdala","volume":"23","author":"Huang","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0390","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0014-2999(93)90869-J","article-title":"Effects of cocaine and amphetamine on acetylcholine release in the hippocampus and caudate nucleus","volume":"238","author":"Imperato","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0395","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.bbrc.2012.11.077","article-title":"Lsamp-\/- mice display lower sensitivity to amphetamine and have elevated 5-HT turnover","volume":"430","author":"Innos","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0400","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/archpsyc.1976.01770030024003","article-title":"Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms","volume":"33","author":"Janowsky","year":"1976","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0405","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0301-0082(03)00085-6","article-title":"Dopamine: a potential substrate for synaptic plasticity and memory mechanisms","volume":"69","author":"Jay","year":"2003","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0410","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1038\/sj.npp.1301572","article-title":"Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence","volume":"33","author":"Jayaram-Lindstrom","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0415","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/01.jcp.0000144893.29987.e5","article-title":"Effects of naltrexone on the subjective response to amphetamine in healthy volunteers","volume":"24","author":"Jayaram-Lindstrom","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0420","first-page":"224","article-title":"Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia","volume":"26","author":"Jody","year":"1990","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0425","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0896-6273(04)00247-8","article-title":"Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior","volume":"42","author":"John","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0430","doi-asserted-by":"crossref","first-page":"854285","DOI":"10.1155\/2012\/854285","article-title":"Functional role of adult hippocampal neurogenesis as a therapeutic strategy for mental disorders","volume":"2012","author":"Jun","year":"2012","journal-title":"Neural Plast"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0435","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/j.1476-5381.1994.tb17152.x","article-title":"Regional effects of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine release and metabolism in the rat brain","volume":"113","author":"Karoum","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0440","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1001\/archpsyc.63.11.1199","article-title":"Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women","volume":"63","author":"Kennedy","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0445","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0306-4522(98)00018-9","article-title":"D1 and D2 dopamine receptor mediation of amphetamine-induced acetylcholine release in nucleus accumbens","volume":"86","author":"Keys","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0450","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0455","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.neuint.2012.03.002","article-title":"Effects of amphetamine on dopamine release in the rat nucleus accumbens shell region depend on cannabinoid CB1 receptor activation","volume":"60","author":"Kleijn","year":"2012","journal-title":"Neurochem Int"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0460","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1360-0443.2006.01586.x","article-title":"The neurobiology of addiction: a neuroadaptational view relevant for diagnosis","volume":"101","author":"Koob","year":"2006","journal-title":"Addiction"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0465","doi-asserted-by":"crossref","first-page":"9235","DOI":"10.1073\/pnas.93.17.9235","article-title":"Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects","volume":"93","author":"Laruelle","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0470","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1038\/npp.2013.111","article-title":"Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases","volume":"38","author":"Lasser","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0475","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1152\/physrev.00005.2009","article-title":"Reward processing by the opioid system in the brain","volume":"89","author":"Le Merrer","year":"2009","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0480","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.neuron.2012.09.012","article-title":"Neuromodulation of brain states","volume":"76","author":"Lee","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0485","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0306-3623(98)00190-6","article-title":"Neurotrophin-dependent modulation of glutamatergic synaptic transmission in the mammalian CNS","volume":"31","author":"Lessmann","year":"1998","journal-title":"Gen Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0490","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0006-3223(93)90192-G","article-title":"Methylphenidate increases thought disorder in recent onset schizophrenics, but not in normal controls","volume":"34","author":"Levy","year":"1993","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0495","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.schres.2013.03.019","article-title":"A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities","volume":"147","author":"Lindenmayer","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0500","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tins.2011.07.006","article-title":"A neoHebbian framework for episodic memory; role of dopamine-dependent late LTP","volume":"34","author":"Lisman","year":"2011","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0505","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1101\/lm.54603","article-title":"BDNF and activity-dependent synaptic modulation","volume":"10","author":"Lu","year":"2003","journal-title":"Learn Mem"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0510","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1523\/JNEUROSCI.5124-03.2004","article-title":"A single infusion of brain-derived neurotrophic factor into the ventral tegmental area induces long-lasting potentiation of cocaine seeking after withdrawal","volume":"24","author":"Lu","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0515","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0169-328X(97)00136-8","article-title":"Expression of dopamine transporter and vesicular monoamine transporter 2 mRNAs in rat midbrain after repeated amphetamine administration","volume":"49","author":"Lu","year":"1997","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0520","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.tins.2011.06.007","article-title":"Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder","volume":"35","author":"Mahan","year":"2012","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0525","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.neuron.2004.09.012","article-title":"LTP and LTD: an embarrassment of riches","volume":"44","author":"Malenka","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0530","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00213-012-2925-4","article-title":"Interaction between the mGlu receptors 5 antagonist, MPEP, and amphetamine on memory and motor functions in mice","volume":"226","author":"Manago","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0535","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0306-4522(01)00284-6","article-title":"Augmented motor activity and reduced striatal preprodynorphin mRNA induction in response to acute amphetamine administration in metabotropic glutamate receptor 1 knockout mice","volume":"106","author":"Mao","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0540","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nn.2300","article-title":"Stability of surface NMDA receptors controls synaptic and behavioral adaptations to amphetamine","volume":"12","author":"Mao","year":"2009","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0545","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejphar.2009.08.046","article-title":"Cognitive impairment in major depression","volume":"626","author":"Marazziti","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0550","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2165\/11633130-000000000-00000","article-title":"Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date","volume":"72","author":"Mathews","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0555","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bbr.2007.07.024","article-title":"Repeated amphetamine administration outside the home cage enhances drug-induced Fos expression in rat nucleus accumbens","volume":"185","author":"Mattson","year":"2007","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0560","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.neuro.22.1.295","article-title":"Neurotrophins and synaptic plasticity","volume":"22","author":"McAllister","year":"1999","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0565","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2009.04.022","article-title":"A meta-analysis of depression severity and cognitive function","volume":"119","author":"McDermott","year":"2009","journal-title":"J Affect Disord"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0570","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fnsys.2011.00060","article-title":"The role of BDNF\/TrkB signaling in acute amphetamine-induced locomotor activity and opioid peptide gene expression in the rat dorsal striatum","volume":"5","author":"McGinty","year":"2011","journal-title":"Front Syst Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0575","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hup.2325","article-title":"The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I\/II disorder","volume":"28","author":"McIntyre","year":"2013","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0580","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0006-8993(02)03160-8","article-title":"Brain-derived neurotrophic factor expression is increased in the rat amygdala, piriform cortex and hypothalamus following repeated amphetamine administration","volume":"949","author":"Meredith","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0585","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/sj.bjp.0703066","article-title":"On the mechanism of d-amphetamine-induced changes in glutamate, ascorbic acid and uric acid release in the striatum of freely moving rats","volume":"129","author":"Miele","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0590","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev.clinpsy.2.022305.095332","article-title":"The psychopathology and treatment of bipolar disorder","volume":"2","author":"Miklowitz","year":"2006","journal-title":"Annu Rev Clin Psychol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0595","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0022-3565(24)38982-7","article-title":"Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors","volume":"295","author":"Millan","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0600","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/0006-2952(80)90429-3","article-title":"In vivo monoamine oxidase inhibition by d-amphetamine","volume":"29","author":"Miller","year":"1980","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0605","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0610","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1095\/biolreprod36.1.47","article-title":"Interactions between prolactin and dopaminergic neurons","volume":"36","author":"Moore","year":"1987","journal-title":"Biol Reprod"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0615","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1705","article-title":"Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin","volume":"30","author":"Morgenthaler","year":"2007","journal-title":"Sleep"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0620","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/syn.20591","article-title":"Increased synapses in the medial prefrontal cortex are associated with repeated amphetamine administration","volume":"63","author":"Morshedi","year":"2009","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0625","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1471-4159.2009.05911.x","article-title":"Behavioral sensitization to amphetamine is not accompanied by changes in glutamate receptor surface expression in the rat nucleus accumbens","volume":"109","author":"Nelson","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0630","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2004.09.007","article-title":"Identification of separable cognitive factors in schizophrenia","volume":"72","author":"Nuechterlein","year":"2004","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0635","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-25758-2_8","article-title":"Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the alpha7 nicotinic receptor","volume":"211\u2013232","author":"Olincy","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0640","doi-asserted-by":"crossref","first-page":"RC184","DOI":"10.1523\/JNEUROSCI.21-23-j0002.2001","article-title":"Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine","volume":"21","author":"Olive","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0645","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1017\/S1461145708009383","article-title":"Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia","volume":"12","author":"Olsson","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0650","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0306-4522(93)90355-J","article-title":"The chemical nature of the main central excitatory transmitter: a critical appraisal based upon release studies and synaptic vesicle localization","volume":"56","author":"Orrego","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0655","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11606-011-1633-9","article-title":"Different black box warning labeling for same-class drugs","volume":"26","author":"Panagiotou","year":"2011","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0660","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.neulet.2008.01.015","article-title":"Upregulation of metabotropic glutamate receptor 8 mRNA expression in the rat forebrain after repeated amphetamine administration","volume":"433","author":"Parelkar","year":"2008","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0665","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/01.jcp.0000246212.03530.fd","article-title":"A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression","volume":"26","author":"Patkar","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0670","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0278-5846(97)00040-7","article-title":"Ritanserin administration potentiates amphetamine-stimulated dopamine release in the rat prefrontal cortex","volume":"21","author":"Pehek","year":"1997","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0675","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00213-010-1914-8","article-title":"Impact of metabotropic glutamate 2\/3 receptor stimulation on activated dopamine release and locomotion","volume":"211","author":"Pehrson","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0680","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1476-5381.2008.00048.x","article-title":"Emerging strategies for exploiting cannabinoid receptor agonists as medicines","volume":"156","author":"Pertwee","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0685","doi-asserted-by":"crossref","first-page":"104105","DOI":"10.1100\/2012\/104105","article-title":"The nicotinic acetylcholine receptor as a target for antidepressant drug development","volume":"2012","author":"Philip","year":"2012","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0690","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuron.2012.08.036","article-title":"Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior","volume":"76","author":"Picciotto","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0695","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0893-133X(01)00333-5","article-title":"5-HT2A and 5-HT2C\/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum","volume":"26","author":"Porras","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0700","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4088\/JCP.v60n0210c","article-title":"Early augmentation of sertraline with methylphenidate","volume":"60","author":"Postolache","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0705","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.tips.2011.06.008","article-title":"The delta opioid receptor: an evolving target for the treatment of brain disorders","volume":"32","author":"Pradhan","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0710","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1523\/JNEUROSCI.4936-09.2010","article-title":"Essential role of dopamine D2 receptor in the maintenance of wakefulness, but not in homeostatic regulation of sleep, in mice","volume":"30","author":"Qu","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0715","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1523\/JNEUROSCI.6165-09.2010","article-title":"Amphetamine-associated contextual learning is accompanied by structural and functional plasticity in the basolateral amygdala","volume":"30","author":"Rademacher","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0720","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1124\/pr.111.004598","article-title":"Functional selectivity at the mu-opioid receptor: implications for understanding opioid analgesia and tolerance","volume":"63","author":"Raehal","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0725","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.brainres.2007.12.052","article-title":"Environmental enrichment increases amphetamine-induced glutamate neurotransmission in the nucleus accumbens: a neurochemical study","volume":"1197","author":"Rahman","year":"2008","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0730","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4088\/JCP.v69n0112","article-title":"Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial","volume":"69","author":"Ravindran","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0735","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0022-3565(25)24116-7","article-title":"Relationship between self-administration of amphetamine and monoamine receptors in brain: comparison with cocaine","volume":"248","author":"Ritz","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0740","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1126\/science.2820058","article-title":"Cocaine receptors on dopamine transporters are related to self-administration of cocaine","volume":"237","author":"Ritz","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0745","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12035-009-8053-4","article-title":"A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters","volume":"39","author":"Robertson","year":"2009","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0750","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1016\/0006-2952(85)90201-1","article-title":"Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl","volume":"34","author":"Robinson","year":"1985","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0755","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1196\/annals.1369.064","article-title":"Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs","volume":"1074","author":"Rothman","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0760","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.mp.4001949","article-title":"Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies","volume":"12","author":"Ruhe","year":"2007","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0765","first-page":"200","article-title":"Effects of cannabinoids on the anxiety-like response in mice","volume":"58","author":"Rutkowska","year":"2006","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0770","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1128\/MCB.05896-11","article-title":"Dopamine-regulated microRNA MiR-181a controls GluA2 surface expression in hippocampal neurons","volume":"32","author":"Saba","year":"2012","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0775","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2011.07.036","article-title":"Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders","volume":"62","author":"Sanacora","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0780","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2165\/11593070-000000000-00000","article-title":"Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults","volume":"25","author":"Santosh","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0785","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pneurobio.2009.01.009","article-title":"5-HT(1A) receptor function in major depressive disorder","volume":"88","author":"Savitz","year":"2009","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0790","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1601-183X.2008.00430.x","article-title":"Amphetamine-induced locomotion and gene expression are altered in BDNF heterozygous mice","volume":"7","author":"Saylor","year":"2008","journal-title":"Genes Brain Behav"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0795","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.physbeh.2008.12.001","article-title":"Individual differences in amphetamine sensitization, behavior and central monoamines","volume":"96","author":"Scholl","year":"2009","journal-title":"Physiol Behav"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0800","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/0269881111412095","article-title":"Systematic review of national and international guidelines on attention-deficit hyperactivity disorder","volume":"26","author":"Seixas","year":"2011","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0805","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.brainres.2010.02.062","article-title":"Regulation of group I metabotropic glutamate receptor expression in the rat striatum and prefrontal cortex in response to amphetamine in vivo","volume":"1326","author":"Shaffer","year":"2010","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0815","doi-asserted-by":"crossref","first-page":"259349","DOI":"10.1155\/2012\/259349","article-title":"Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders","volume":"2012","author":"Shen","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0810","doi-asserted-by":"crossref","first-page":"11041","DOI":"10.1523\/JNEUROSCI.2898-06.2006","article-title":"Amphetamine-induced place preference and conditioned motor sensitization requires activation of tyrosine kinase receptors in the hippocampus","volume":"26","author":"Shen","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0820","doi-asserted-by":"crossref","first-page":"8191","DOI":"10.1073\/pnas.94.15.8191","article-title":"Brain-derived neurotrophic factor rapidly enhances phosphorylation of the postsynaptic N-methyl-D-aspartate receptor subunit 1","volume":"94","author":"Suen","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0825","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.neuron.2011.02.010","article-title":"How addictive drugs disrupt presynaptic dopamine neurotransmission","volume":"69","author":"Sulzer","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0830","doi-asserted-by":"crossref","first-page":"7342","DOI":"10.1523\/JNEUROSCI.4603-04.2005","article-title":"Dopamine receptor stimulation modulates AMPA receptor synaptic insertion in prefrontal cortex neurons","volume":"25","author":"Sun","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0835","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/npp.2010.160","article-title":"Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: a decade of progress","volume":"36","author":"Swanson","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0840","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev.neuro.25.112701.142826","article-title":"The role of hypocretins (orexins) in sleep regulation and narcolepsy","volume":"25","author":"Taheri","year":"2002","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0845","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.euroneuro.2008.11.003","article-title":"CB1 receptor knockout mice are hyporesponsive to the behavior-stimulating actions of d-amphetamine: role of mGlu5 receptors","volume":"19","author":"Tzavara","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0850","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/0269881109106925","article-title":"Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania","volume":"25","author":"Valvassori","year":"2011","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0855","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.neuropharm.2011.04.001","article-title":"Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT(1A) receptor knockout mice: implications for schizophrenia","volume":"61","author":"van den Buuse","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0860","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00004850-198804000-00002","article-title":"Dextro-amphetamine diminishes negative symptoms in schizophrenia","volume":"3","author":"van Kammen","year":"1988","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0870","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.tips.2013.07.005","article-title":"Mechanisms of dopamine transporter regulation in normal and disease states","volume":"34","author":"Vaughan","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0865","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.chc.2012.07.005","article-title":"Pharmacotherapy of pediatric attention-deficit\/hyperactivity disorder","volume":"21","author":"Vaughan","year":"2012","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0875","series-title":"In Behavioral Neurobiology Of Bipolar Disorder And Its Treatment","first-page":"107","article-title":"The role of the aminergic systems in the pathophysiology of bipolar disorder","author":"Walderhaug","year":"2011"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0880","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/(SICI)1098-2396(199602)22:2<114::AID-SYN4>3.0.CO;2-G","article-title":"D1 and D2 receptor regulation of preproenkephalin and preprodynorphin mRNA in rat striatum following acute injection of amphetamine or methamphetamine","volume":"22","author":"Wang","year":"1996","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0885","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-010-1825-8","article-title":"The role of the dynorphin-\u03ba opioid system in the reinforcing effects of drugs of abuse","volume":"210","author":"Wee","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0890","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2261-12-41","article-title":"Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review","volume":"12","author":"Westover","year":"2012","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0895","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1523\/JNEUROSCI.21-05-01787.2001","article-title":"Dopaminergic role in stimulant-induced wakefulness","volume":"21","author":"Wisor","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0900","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuropharm.2004.07.006","article-title":"Psychomotor stimulants and neuronal plasticity","volume":"47","author":"Wolf","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0905","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00213-007-0974-x","article-title":"The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2\/3 agonist, LY379268, in mouse models predictive of antipsychotic activity","volume":"196","author":"Woolley","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0910","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/sj.npp.1301463","article-title":"Acute amphetamine exposure selectively desensitizes kappa-opioid receptors in the nucleus accumbens","volume":"33","author":"Xia","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0915","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1111\/j.1471-4159.2010.07073.x","article-title":"Amphetamine modulation of long-term potentiation in the prefrontal cortex: dose dependency, monoaminergic contributions, and paradoxical rescue in hyperdopaminergic mutant","volume":"115","author":"Xu","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0920","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1046\/j.1471-4159.1996.67010352.x","article-title":"Acute and repeated systemic amphetamine administration: effects on extracellular glutamate, aspartate, and serine levels in rat ventral tegmental area and nucleus accumbens","volume":"67","author":"Xue","year":"1996","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0925","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1017\/S1092852900016138","article-title":"The dopaminergic projection system, basal forebrain macrosystems, and conditioned stimuli","volume":"13","author":"Zahm","year":"2008","journal-title":"CNS Spectr"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0930","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.fitote.2010.05.007","article-title":"Effect of rhynchophylline on central neurotransmitter levels in amphetamine-induced conditioned place preference rat brain","volume":"81","author":"Zhou","year":"2010","journal-title":"Fitoterapia"},{"key":"10.1016\/j.pharmthera.2014.03.005_bb0935","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0022-3565(24)38993-1","article-title":"Regulation of the human norepinephrine transporter by cocaine and amphetamine","volume":"295","author":"Zhu","year":"2000","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725814000667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725814000667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:51:22Z","timestamp":1759009882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725814000667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":187,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0163725814000667"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2014.03.005","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical pharmacology of amphetamine: Implications for the treatment of neuropsychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2014.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}